Valeant’s OTC Pickups Emphasize Specialty Segments, Growth Markets
This article was originally published in The Tan Sheet
Executive Summary
The Montreal pharma company includes a focus on OTCs and generics in its quest to grow while remaining relatively immune to patent cliffs and scaled-back Rx reimbursements. Valeant’s recent PEDiNOL Pharmacal acquisition, including OTC podiatry products, fits into its niche category strategy.